ReviewInfection and drug resistance2022
Molecular Characterization of Carbapenem-Resistant
Review in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 54 citations in OpenAlex.
- AI-assisted MALDI-TOF MS for identifying carbapenem resistance in clinicalEmerging microbes & infections · 2026Article
- Article
- Article
- A monoclonal antibody targeting OXA23 restores carbapenem susceptibility in global epidemic carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Genomic epidemiology of carbapenem resistance inJAC-antimicrobial resistance · 2026Article
- The Novel Carbapenem, JDB/PQ-1-219, Has Potent Broad Spectrum Activity against Multi-Drug ResistantACS infectious diseases · 2026Article
- Cross-Species Dissemination of Pandrug-ResistantMicroorganisms · 2026Article
- Multiplex Lateral Flow Immunochromatographic Assay Is an Effective Method to Detect Carbapenemases in Non-SusceptibleJournal of clinical medicine · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Imipenem-Induced Transcriptional Responses of Porin, Efflux Pumps, and Carbapenemase Genes in Clinical Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Clonal Dynamics and Antimicrobial Resistance of Bloodstream Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Application value of Xpert Carba-R combined with LAMP in the diagnosis and prognosis of carbapenem-resistant Gram-negative bacilli pneumonia.Microbiology spectrum · 2026Article
- Mechanistic and clinical insights into a PmrB mutation driving colistin resistance and virulence in Acinetobacter baumannii.Scientific reports · 2026Article
- Exploring the Antibacterial and Antioxidant Effects ofInternational journal of microbiology · 2026Article
- Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- Genomic insights into multidrug resistance in clinicalFrontiers in microbiology · 2026Article
- Molecular detection of carbapenemases in critical microorganisms since the onset of the COVID-19 pandemic in Peru.JAC-antimicrobial resistance · 2025Article
- The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review.Journal of clinical medicine · 2025Review
- Unveiling meropenem resistance and co-resistance patterns in Klebsiella pneumoniae and Acinetobacter baumannii: a global genome analysis using ML/DL and association mining.BMC microbiology · 2025Article
- Distribution of antimicrobial resistance genes and virulence genes in different genotypes of Acinetobacter baumannii.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenemases are β-lactamase enzymes that hydrolyze a variety of β-lactams including carbapenem and belong to different Ambler classes (A, B, D). These enzymes can be encoded by plasmid or chromosomal-mediated genes. The major issues associated with carbapenemases-producing organisms are compromising the activity and increasing the resistance to carbapenems which are the last resort antibiotics used in treating serious infections. The global increase of pathogen, carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.